Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Naloxone Product Approval Standards May See Changes

Executive Summary

Advisory committees will weigh adequacy of current pharmacokinetic requirements and pediatric dosing for novel formulations of the opioid overdose reversal agent.


Related Content

Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals
'Repeal And Replace' Going Relatively Well For Pharma So Far
Naloxone Efficacy Standard Changes Could Impact Amphastar's Pending NDA
Bring Naloxone To Opioid Overdoses: FDA Crowd-Sources Smartphone Apps
Opioid Abuse: White House Expanding Access To Buprenorphine, Naloxone
FDA's Opioid Action Plan Could Clear Califf Nomination Roadblock
Indivior Has Some Explaining To Do At R&D Day After Nasal Naloxone Spray Fails To Get FDA OK
Keeping Track: FDA Issues Three Four-Month Approvals: Ninlaro, Darzalex, And Narcan Nasal Spray
FDA Ponders Drug Pricing In Opioid Abuse Analysis
FDA’s “Balanced Approach” To Opioids Extols Naloxone Auto-injector


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts